This document discusses quality metrics and their importance in measuring and improving pharmaceutical quality. It defines quality metrics as standards used to assess efficiency, performance, and quality. Quality metrics help ensure what is measured gets recorded, monitored, controlled, and improved. The document outlines key quality metrics like batch acceptance rate, product complaint rate, and invalid OOS rate. It also discusses FDA's guidance around voluntary submission of quality metrics data and the benefits this can provide manufacturers. Overall quality metrics are presented as an important tool for continual improvement and assurance of patient safety.
OOS and OOT investigation is always a challenging task. This slide may help for a better understanding of investigation procedure according to regulatory requrement.
Presentation on data integrity in Pharmaceutical IndustrySathish Vemula
Presentation on data integrity in Pharmaceutical Industry
Contents:
- Definition & Basics
- Criteria for integrity of laboratory data
- Regulatory Requirements
- Barriers to Complete Data
- Possible data integrity problems
- Previous observations
- FDA Warning Letters – 2013
- FDA Warning Letters – 2014
- FDA 483’s related to data integrity
- EU – Non compliance Reports
- WHO - Notice of Concern
- Summary of Data Integrity issues
- Consequences- Rebuilding Trust
- Conclusion
These slides were used for a invited presentation @ Patheon Seminar – Bridgewater, NJ, 31 July 2014.
Some modification have been made to connect the dots for the audience who will review this slide-deck on the internet.
This presentation provides a very brief snap-shot of a day long training program conducted recently at a company in India. In preparing the day long training session I had asked the following questions; (1) How to effectively communicate to an audience of a group of young and bright Indian professionals in any company in India and their supervisors/management about the importance of cGMPs and QbD? (2) How do I understand their challenges, perspectives and biases? (3) How do I connect with them to share the joy of Quality by Design?
The response received has been overwhelming from the audiences in India and yesterday at the Patheon Seminar in Bridgewater, NJ. I hope you will also the see some of the important dots and the connections. How this content connects to regulatory requirements is not covered in this slide deck – it connects via ‘A, B, C, D’ to 21 CFR, Quality Systems Approach to cGMP, ICH 7, 8, 9, 10, and 11.
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
OOS and OOT investigation is always a challenging task. This slide may help for a better understanding of investigation procedure according to regulatory requrement.
Presentation on data integrity in Pharmaceutical IndustrySathish Vemula
Presentation on data integrity in Pharmaceutical Industry
Contents:
- Definition & Basics
- Criteria for integrity of laboratory data
- Regulatory Requirements
- Barriers to Complete Data
- Possible data integrity problems
- Previous observations
- FDA Warning Letters – 2013
- FDA Warning Letters – 2014
- FDA 483’s related to data integrity
- EU – Non compliance Reports
- WHO - Notice of Concern
- Summary of Data Integrity issues
- Consequences- Rebuilding Trust
- Conclusion
These slides were used for a invited presentation @ Patheon Seminar – Bridgewater, NJ, 31 July 2014.
Some modification have been made to connect the dots for the audience who will review this slide-deck on the internet.
This presentation provides a very brief snap-shot of a day long training program conducted recently at a company in India. In preparing the day long training session I had asked the following questions; (1) How to effectively communicate to an audience of a group of young and bright Indian professionals in any company in India and their supervisors/management about the importance of cGMPs and QbD? (2) How do I understand their challenges, perspectives and biases? (3) How do I connect with them to share the joy of Quality by Design?
The response received has been overwhelming from the audiences in India and yesterday at the Patheon Seminar in Bridgewater, NJ. I hope you will also the see some of the important dots and the connections. How this content connects to regulatory requirements is not covered in this slide deck – it connects via ‘A, B, C, D’ to 21 CFR, Quality Systems Approach to cGMP, ICH 7, 8, 9, 10, and 11.
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
Quality measures are tools that help us measure or quantify healthcare processes, outcomes, patient perceptions, and organizational structure and/or systems that are associated with the ability to provide high-quality health care and/or that relate to one or more quality goals for health care.
Validation.
Validation is establishing documented evidence which provides a high degree of assurances that a specific process or equipment will consistently produce a product or result meeting its predetermined specifications and quality attributes”.
A system must be qualified to operate in a validated process
The results of analytical procedures should be:
— reliable
— accurate
— reproducible
The characteristics that should be considered during validation of analytical methods are:
— specificity
— linearity
— range
— accuracy
— precision
— detection limit
— quantitation limit
— robustness
This is a presentation based on ICH Q10, Pharmaceutical Quality System, It was shared recently with participants of a training session arranged by Ingrope Information Services karachi at marriot Hotel. I am uploading for the benefits of all pharma colleagues, specially the junior ones.
A presentation of Pharmaceutical Quality System ICH Q 10 Model. This presentation was shared lately in a session arranged ny Ingrope Information Services, Karachi, at Marriot Hotel.
A quality audit, also known as a quality assurance audit or compliance audit, is a systematic examination and evaluation of processes, systems, and records to determine compliance with established quality standards, regulations, guidelines, and best practices. The purpose of a quality audit is to identify areas of non-compliance, assess the effectiveness of quality management systems, and identify opportunities for improvement. Here are some key aspects of a quality audit
Drug Discovery path
Pharma R & D –overview
Discovery & Development
Preclinical research
Clinical Trial
NDA and FDA Approval
Post marketing data
References
Optical Rotation and Polarimeter by Dr. A. AmsavelDr. Amsavel A
Isomers and enantiomers
Specific Optical Rotation
Polarimeter
Instrumentation and Operation
Factors affect the Optical Rotation
Calibration
Application Specifically Pharmaceutical Industries
Personal Hygiene for pharma industry-Dr. A. AmsavelDr. Amsavel A
Personal hygiene
Source of Contamination and control
GMP Requirement /Guideline
Procedures & Records
Protective Clothing & gowning
Health Examination
Hand wash – How and when
Training & Practice
by Dr. A. Amsavel
Awareness on Cancer
what are the causes for cancer
Terminology
Classification of Cancers
Signs and Symptoms
Stages of Cancers (TSM)
Types of Cancer Treatments
Surgery, Chemotherapy, Radiation Therapy etc
Side effects on treatment
Palliative care
FTIR SPECTROSCOPY,
Principle, Theory, Instrumentation and Application in Pharmaceutical Industry
IR Spectroscopy- Absorption Theory
Type of Vibrations & Vibration Energy level
FTIR Spectrophotometer-Instrumentation
Operation of the Spectrophotometer
Qualification & Calibration
IR Absorption by Organic compounds
Application
FDA citation in FTIR Analysis-Pharmaceutical Industries
UV -Vis Spectrophotometry- Principle, Theory, Instrumentation and Application...Dr. Amsavel A
UV -Vis Spectrophotometry- Principle, Theory, Instrumentation and Application in Pharmaceutical Industry Dr. A. Amsavel.
UV &Visible Spectroscopy-Absorption Theory
Electronic Transitions
Beer- Lambert Law
Chromophores & Auxochrome
Factors Influence the Absorption
UV-Vis Spectrophotometer-Instrumentation
Operation of the Spectrophotometer
Qualification & Calibration
Application
Handling of Refernce Standards_Dr.A.Amsavel Dr. Amsavel A
Definition
Requirements
Guidelines
Pharmacopiea
Types of Reference Standards
SOP for handling of Reference Standards
Qualification of Secondary Standards
Assigning Potency, Storage and Use
Documents & Records
Contamination Control in Cleanrooms_Dr.A. AmsavelDr. Amsavel A
Basic’s of Contamination
Sources of Contamination
Environment Specification
Elements of Cleanroom Design and Qualification
Definitions
Control of Contaminations
People, Cleaning, Environment & Material
Operation, Monitoring and Control
Documents and Records
Handling of Customer Complaint_Dr.A.AmsavelDr. Amsavel A
Reference Guideline
Definitions
GMP Requirement: 21 CFR § 211.198 and ICH Q7
Procedure for Handling of Complaints
Complaint Investigation
Remedial action and CAPA
Report preparation
Response to customer
Verification of CAPA effectiveness
Review of Complaints
Review of Quality Control Record and Analytical Data by Dr. A. AmsavelDr. Amsavel A
Review of Quality Control Record and Analytical Data
Objective and Requirement for Analytical data review
Role of Analyst and reviewer,
Procedure and checklist for review of records/data
Review of traceable /associated documents
Review of calibration, Reference standard record, sampling reports,
Review of Audit trail
Role of Analyst & Reviewer
Review of chromatograms& audit trail,
Data Integrity & Good Record Practice
FDA Citations
Volumetric Analysis
Titration Basics
Reaction, End point & Indicators
Types of Titrations
Acid – Base Theory & Principles
Acid Base titration
Non- Aqueous Titration
Precipitation Titration
Complexometric Titration
Oxidation- Reduction Titration
Calculation
General Information
Errors
Volumetric Analysis
Types of titration
Acid- Base Theory
Reaction, End Point & Indicators
Acid- Base titration
Titration curve
Non- Aqueous Titration
Precipitation Titration
Complexometric Titration
Oxidation- Reduction Titration,
Calculation. Errors
General Informations,
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
3. Introduction
GMP and Quality systems are dynamic .
Regulations and requirements for Pharmaceutical
industries become stringent YOY
Pharmaceutical Quality for the 21st Century -ICH Q9, Q10
& Q11 in addition to Q7 and other guideline
Latest expectation from Regulatory Agencies is QM
4. Metric- Meaning
Standards of measurement by which efficiency,
performance, progress, or Quality of a Plan,
Process, or Product can be assessed
5. Measures to Improvements
What does not get Measured, Can not be Recorded
What does not get Recorded, Can not be Monitored
What does not get Monitored, Can not be Controlled
What does not get Controlled, Can not be Improved
6. Why Quality Metrics and Who
Manufacturers have extensive knowledge about critical
product and process parameters and quality attributes
Organization to measure performance both inside and in
its competitive environment
Uses data and analysis in decision making
Manufacturers strive for continual improvement
Use QM for Improvements & Growth
7. FDA Expectation
“A maximally efficient, agile, flexible pharmaceutical
manufacturing sector that reliably produces high
quality drugs without extensive regulatory oversight.”
-Janet Woodcock
8. Quality Metrics & FDA Guidance
Establish Quality Metrics
Objective/goal, measurement and method
Measure and PDCA
Register to FDA as volunteer to Submit QM
Submit the Quality metrics to FDA for review
9. Quality Metrics-FDA
Supports continual improvement of process performance and
product quality.
Supports continual improvement of PQS
Important element of oversight and controls over the
manufacture of drugs to ensure quality (section 501 FD&C Act)
Encourage use of modern, more efficient manufacturing
technologies.
Improvement by industry leads to more robust manufacturing
processes
Regulatory flexibility for post-approval changes
10. Quality Metrics Submission -FDA
Submission of QM to FDA is not a requirement, It is voluntary
reporting program.
FDA does not intend to take enforcement action based on
errors in a quality metrics data submission, provided the
submission is made in good faith
FDA does not publicly disclose information
Providing industry an incentive too
Participation in the program demonstrates:
A willingness to proactively engage with the Agency
A commitment to increasing transparency between industry &
FDA
11. Benefits of Participation
Work with establishments towards early resolution of
potential quality problems
Improved Inspection effectiveness
FDA is considering use of calculated metrics as an
element of the post-approval manufacturing change
reporting program
Reduction in inspection frequency
Inclusion on the Quality Metrics Reporters List
12. Quality Metrics
Quality can be measured on different levels and for many
processes
It must be useful and it can enable a company to reach a
high quality performance
Quality Metrics are not just a measure of Quality
Assurance activities but a measure all activities that
ensure quality in the product.
This should be effective.
13. Quality Metrics: Key Measures
# Process Measurement
1 Robustness of Commercial
Manufacturing Process
Batch acceptance/
rejection rate
2 Robustness of Laboratory
Operation
Invalidate OOS rate
3 Voice of the Patient/Customer Product complaint rate
4 Periodic & timely quality
review
Deviation from timely
PQR
14. Batch Acceptance Rate
Batch Acceptance Rate =
The number of accepted lots /
No. of lots produced ( no exclusion) in a given period
Possibly intermediates in in a given period.
Calculate lot acceptance rate by the month,
Based on each month trend
Set Goal for lot acceptance
Show improvement each month
15. Product Complaint Rate
Product Complaint Rate =
The number of product quality complaints received for
the product
= ----------------------------------------------------------------
The total number of lots of the product released
in the same timeframe
Calculate complaint rate by the month / Quarter
Trend
Set Goal to reduce the complaint
Eliminate the repeated complaint.
16. Invalid OOS Rate
Measure for both Batch approval & Stability OOS
Invalidated Out-of-Specification (OOS) Rate (IOOSR)=
Number of OOS test results for lot release invalidated due to an
aberration of the measurement process/ The total number of lot
release OOS test results in the current reporting timeframe of tests
performed in the same timeframe.
= No. of invalidated OOS test results for lot release
The total No. of batch release
= No of OOS test results in long-term stability tested invalidated
Total No . of long-term stability OOS tested
As per guideline – No of tests not even batches Eg. Assay, related
substances , LOD, ash
17. APR Completion Rate
Measure for APR or PQR
If the associated APRs or PQRs were completed within 30 days
of annual due date for the product.
The number of APRs or PQRs required for the product.
Calculate lot acceptance rate by the month, each month.
Trend Goal – improvement each month
Establish a goal of reduction of the trend
= No. of invalidated OOS test results for lot release
The total No. of batch release
= No of OOS test results in long-term stability tested invalidated
Total No . of long-term stability OOS tested
As per guideline – No of tests not even batches Eg. Assay, related
substances , LOD, ash
18. Goals for FDA’s application of QM
Develop objective measures
Conduct continual monitoring, assessment, and reporting
on the state of quality across the inventory of drug
products and facilities regulated by FDA
Monitor the quality of products and sites by utilizing
information from exploratory and explanatory studies to
detect critical signals (e.g. trends, seasonal effects, cyclic
patterns).
Senior management commitment to quality
CAPA effectiveness (retraining, preventive actions)
19. Other Metrics
Facilities & Utilities
Percentage failure rate for PW system
TOC/Conductivity being out of range
Alert & Action exceedances
HVAC excursions
Temperature/RH/pressure differentials
Out of calibration rates for equipment
Percentage unplanned maintenance
20. Other Metrics
Production
Right first time
Documentation errors
Efficiency
Quality Failure
Rework rate
Reprocessing rate
EM excursion rates
Deviations
21. Other Metrics
QC
QC Laboratory System
OOS rate - Invalidated OOS
Raw material/ Finished Product/ Stability
Testing completed on time
Instrument failure
Supplier quality requirements ▫ Distribution system
measurements
22. Other Metrics-QA
QA
Right-First-Time
Process performance and capability -CP & Cpk
Deviations without assigned root cause
Repeated OOS / Deviations
Quality complaint – other than quality
Supplier quality requirements
Distribution system measurements
23. Purpose
to ensure patient safety and Quality
Ultimately Pharmaceutical Quality is
to Assure every dose is Safe and
Effective, free of Defects and
Adulteration/comtamination.
24. Reference
Submission of Quality Metrics Data Guidance for Industry:
U.S. Department of Health and Human Services
Food and Drug Administration
November 2016